Dana-Farber Cancer Institute, Boston | Cancer Care

Founded in 1947, Dana-Farber developed from an institution focused on childhood cancer research into a cancer treatment and research organisation serving adults and children. Its work connects laboratory investigation with clinical care, including the development and testing of new medicines and treatment strategies.

The institute is affiliated with Harvard Medical School and forms part of Dana-Farber/Harvard Cancer Center. The latter is an NCI-designated comprehensive cancer centre bringing together several Boston academic institutions. This designation recognises a broad research and clinical infrastructure; it is not a ranking or a guarantee of an individual patient's outcome.

Dana-Farber operates through a main Boston campus and additional care locations rather than a single self-contained hospital service. Adult care has an established collaboration with Brigham and Women's Hospital, while paediatric services involve Boston Children's Hospital. Patients should confirm which organisation and site would provide consultations, procedures, admissions and emergency care, as arrangements can evolve.

The institute is known for disease-focused teams and research in haematological malignancies, cancer biology and immunotherapy. Its scale allows access to multiple specialist disciplines, although the appropriate team and practical availability of services depend on the diagnosis and proposed treatment.

Blood cancers are a substantial focus, including leukaemia, lymphoma, myeloma and related bone marrow disorders. Programmes bring together diagnostic review, drug treatment, transplantation expertise and cellular therapy assessment where relevant. Lymphoma care is organised around the specific subtype, since aggressive and slow-growing lymphomas can require very different approaches.

Breast and lung cancer programmes consider stage, pathology, molecular findings and previous treatment when planning care. In breast cancer, hormone receptors and HER2 status can influence treatment selection. In lung cancer, tumour mutations and immune biomarkers may help determine whether targeted therapy, immunotherapy, chemotherapy or a combination is appropriate.

Rare cancer programmes offer disease-specific assessment where expertise is available, including for selected uncommon solid tumours. For these diagnoses, confirming the pathology can be particularly important. Patients should ask whether the centre has a programme for their exact cancer subtype, rather than assuming that all rare cancers have the same treatment options.

Treatment planning can involve systemic medicines, surgery and radiotherapy, with hospital-based services provided through relevant partner teams. Recommendations depend on the cancer's type and extent, the aim of treatment, previous therapies and the patient's overall health. An international consultation may confirm that treatment available locally remains appropriate rather than recommend travel for a different approach.

Immunotherapy includes medicines that alter immune responses against cancer, such as checkpoint inhibitors, where approved or available in a suitable trial. These treatments are not effective for every cancer and can cause serious immune-related side effects. Early-phase immunotherapy research explores newer approaches, but participation carries uncertainty about benefit and toxicity.

CAR-T cell therapy is available for selected blood cancers, subject to the applicable indication and clinical assessment. It involves collecting immune cells, modifying them and returning them after preparatory treatment. Patients may need a caregiver, close monitoring and an extended stay near the treating facility because complications can require urgent specialist care.

Precision oncology uses tumour characteristics, including molecular test results, to inform treatment choices. Targeted therapy is appropriate only when a relevant biological target and supporting clinical evidence exist. Testing may identify a standard treatment, a trial option or no actionable finding. Patients should ask whether existing results are sufficient or whether repeat tissue or blood testing is needed.

Dana-Farber's research portfolio includes disease-specific studies, early-phase drug development, immunotherapy combinations and cellular therapies. The figure of around 1,100 active oncology clinical trials is indicative rather than a verified, real-time count. Totals can vary according to whether studies are recruiting, continuing follow-up or counted across affiliated institutions; they should not be interpreted as the number of open treatment places.

International patients can ask the relevant clinical team to assess possible studies after reviewing their diagnosis and records. Eligibility may depend on tumour subtype, biomarkers, previous treatments, organ function and a required interval since the last therapy. A promising match does not guarantee enrolment, and screening may require examinations or tests in Boston.

Before travelling, request confirmation of recruitment status, anticipated screening steps and the visit schedule. Ask which expenses the study covers and which remain the patient's responsibility. Trial participation is voluntary, and experimental treatment may not provide benefit.

Start with a records-based enquiry that states the exact diagnosis, current treatment, reason for seeking another opinion and whether trial access is a priority. Request guidance on urgency and whether an initial remote review is available for your country. Do not interrupt treatment at home while awaiting a response unless your treating team advises it.

Plan for more than the first appointment. Confirm where care will take place, likely attendance requirements, caregiver needs and arrangements for complications. Ask how the Boston team would communicate with your local oncologist and provide a treatment summary. Travel bookings should remain flexible until the clinical plan and financial arrangements are clarified.

Contact details below come from the hospital's own published international patient information.

Location: Boston, United States

Email: international@dfci.harvard.edu

Phone: +1 617 632 3000

Website: https://www.dana-farber.org

Languages supported: English, Spanish, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.